<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03693157</url>
  </required_header>
  <id_info>
    <org_study_id>107-052-E</org_study_id>
    <nct_id>NCT03693157</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of FFR Protocol in NTUH System</brief_title>
  <official_title>The Safety and Efficacy of Current FFR Measurement in NTUH Health Care System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital Hsin-Chu Branch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital Hsin-Chu Branch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      FFR-guided PCI has been performed in National Taiwan University Hospital(NTUH) for many&#xD;
      years. Nevertheless, the method of FFR measurement in NTUH is different from that in&#xD;
      literature. In this study, the investigator would like to evaluate the effectiveness and&#xD;
      safety of NTUH experience in FFR prospectively. First, the investigator will record any&#xD;
      intracoronary (IC) injected adenosine-related complications, such as bradyarrhythmia or chest&#xD;
      discomfort. Second, the investigator will follow up on the clinical outcome of the&#xD;
      participants for 2 years, record if any target lesion failure, target vessel failure, target&#xD;
      vessel-related myocardial infarction, and cardiac death. Finally, left ventricular diastolic&#xD;
      pressure, serum pro-brain natriuretic peptide (pro-BNP), and high sensitivity C- reactive&#xD;
      protein (hsCRP) will be checked and determined their relationships with the maximum dosage of&#xD;
      IC adenosine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FFR has been introduced for the determination of physiological ischemia in the myocardium for&#xD;
      many years. Nowadays, FFR-guided PCI is highly recommended for the assessment of physiologic&#xD;
      ischemia in intermediate coronary lesions. FFR-guided PCI has been performed in National&#xD;
      Taiwan University Hospital(NTUH) for many years. Nevertheless, the method of FFR measurement&#xD;
      in NTUH is different from that in literature. In this study, the investigator would like to&#xD;
      evaluate the effectiveness and safety of NTUH experience in FFR prospectively. First, the&#xD;
      investigator will record any intracoronary (IC) injected adenosine-related complications,&#xD;
      such as bradyarrhythmia or chest discomfort. Second, the investigator will follow up on the&#xD;
      clinical outcome of the participants for 2 years, record if any target lesion failure, target&#xD;
      vessel failure, target vessel-related myocardial infarction, and cardiac death. Finally, left&#xD;
      ventricular diastolic pressure, serum pro-brain natriuretic peptide (pro-BNP), and high&#xD;
      sensitivity C- reactive protein (hsCRP) will be checked and determined their relationships&#xD;
      with the maximum dosage of IC adenosine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Adenosine related adverse event</measure>
    <time_frame>24 hours</time_frame>
    <description>Including&#xD;
Bradyarrhythmia including sinus pause and transient AV block&#xD;
Acute respiratory failure define by respiratory distress which need mechanical ventilator support</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major adverse cardiac event (MACE)</measure>
    <time_frame>2 year</time_frame>
    <description>MACE including target lesion failure, target vessel failure, target vessel-related myocardial infarction, and cardiac death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The relationship between left ventricular diastolic pressure and maximum dosage of IC adenosine</measure>
    <time_frame>1 hour</time_frame>
    <description>Determine the correlation of left ventricular diastolic pressure and peak dosage of IC adenosine with FFR protocol in NTUH system</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The relationship between pro-BNP,hs-CRP and maximum dosage of IC adenosine</measure>
    <time_frame>1 day</time_frame>
    <description>Determine the correlation of pro-BNP,,hs-CRP and peak dosage of IC adenosine with FFR protocol in NTUH system</description>
  </other_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Bradyarrhythmia</condition>
  <condition>Dyspnea</condition>
  <condition>Acute Respiratory Failure</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects who had intermediate lesion over the coronary artery and eligible for FFR&#xD;
        examination&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligible for FFR examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to adenosine&#xD;
&#xD;
          -  Severe valvular aortic stenosis&#xD;
&#xD;
          -  Resting heart rate less than 50 beats per minute&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chien-Boon Jong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital, Hsinchu Branch.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chien-Boon Jong, MD</last_name>
    <phone>+88635322140</phone>
    <email>jgboon0407@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital Hsin-Chu branch</name>
      <address>
        <city>Hsinchu</city>
        <zip>300</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chien-Boon Jong, MD</last_name>
      <phone>035322140</phone>
      <email>jgboon0407@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chien-Boon Jong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 27, 2018</study_first_submitted>
  <study_first_submitted_qc>October 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

